EXOSC4 Antibody

What is EXOSC4 and why is it an important target for antibody-based research?

EXOSC4 (also known as RRP41, SKI6, p12A) is a non-catalytic component of the RNA exosome complex that participates in RNA processing and degradation. The RNA exosome complex has 3'→5' exoribonuclease activity and is involved in multiple cellular RNA processing and degradation events . EXOSC4 is critical for proper maturation of stable RNA species such as rRNA, snRNA, and snoRNA, and for eliminating RNA processing by-products and non-coding transcripts in the nucleus . In the cytoplasm, it participates in general mRNA turnover and specifically degrades unstable mRNAs containing AU-rich elements (AREs) . Recent research has also implicated EXOSC4 in diseases like epithelial ovarian cancer and certain neurological disorders, making it an important research target .

What types of EXOSC4 antibodies are available and which applications are they validated for?

Currently available EXOSC4 antibodies are primarily rabbit polyclonal antibodies. These have been validated for multiple applications:

Most antibodies show reactivity with human, mouse, and/or rat samples, with positive detection in cell lines including HEK-293T, Jurkat, HeLa, SW480, HCT 116, A-431, and LO2 cells .

How should I optimize western blot protocols for EXOSC4 detection?

For optimal EXOSC4 detection via western blot:

• Sample preparation: Use RIPA buffer with protease inhibitors for protein extraction from cells/tissues.

• Protein loading: Load 20-40 μg of total protein per lane.

• Gel separation: Use 10-12% SDS-PAGE gels as EXOSC4 has a calculated molecular weight of 26 kDa (observed MW: 26-27 kDa) .

• Antibody dilution: Start with manufacturer's recommended dilution (typically 1:1000 for WB) and optimize as needed .

• Blocking: Use 5% BSA or non-fat milk in TBST.

• Controls: Include positive controls from validated cell lines such as HeLa, Jurkat, or HEK-293T cells .

• Detection system: Both chemiluminescence and fluorescence-based detection systems work well.

Note that some researchers report the observed molecular weight may vary slightly from the calculated 26 kDa due to post-translational modifications or sample preparation conditions .

What are the recommended protocols for immunohistochemistry (IHC) using EXOSC4 antibodies?

For optimal IHC results with EXOSC4 antibodies:

• Tissue preparation: Fix tissues with 10% neutral formalin, embed in paraffin, and section at 4 μm thickness .

• Antigen retrieval: Boil sections in 10 mmol/L citrate buffer (pH 6.0) for 20 minutes. Some antibodies may require TE buffer (pH 9.0) for optimal retrieval .

• Blocking: Cover sections with 5% BSA for 10 minutes .

• Antibody incubation: Incubate with anti-EXOSC4 primary antibody at recommended dilution (typically 1:400-1:1600) at 4°C overnight .

• Detection: Use appropriate secondary antibody and DAB chromogenic reagent kit following manufacturer's instructions .

• Evaluation: EXOSC4 staining is typically distributed in both the nucleus and cytoplasm, primarily localized in epithelial cells .

For scoring, combine staining intensity (0=absent, 1=weak, 2=moderate, 3=strong) with the proportion of positive cells (0=0-10%, 1=10-25%, 2=26-50%, 3=51-75%, 4=76-100%), with final scores of 0-3 indicating low expression and 4-7 indicating high expression .

What is the role of EXOSC4 in the RNA exosome complex?

EXOSC4 functions as a non-catalytic component of the RNA exosome complex. Specifically:

• In the RNA exosome core complex (Exo-9), EXOSC4 plays a pivotal role in binding and presenting RNA for ribonucleolysis .

• It serves as a scaffold for association with catalytic subunits and accessory proteins/complexes .

• EXOSC4 has been shown to bind directly to AU-rich element (ARE)-containing RNAs, which are important for regulating mRNA stability .

• It participates in both nuclear RNA processing pathways (including maturation of rRNA, snRNA, and snoRNA) and cytoplasmic mRNA turnover .

• The exosome complex containing EXOSC4 may be involved in immunoglobulin class switch recombination (CSR) and/or variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates .

Understanding these functions is critical for experimental design when targeting EXOSC4 in research studies.

What evidence links EXOSC4 to cancer progression and could it serve as a biomarker?

Recent research has established significant connections between EXOSC4 and cancer progression, particularly in epithelial ovarian cancer (EOC):

These findings suggest EXOSC4 could serve as both a diagnostic biomarker and potential therapeutic target in EOC, with implications for other cancers as well.

What is known about EXOSC4 mutations and associated pathologies?

Research has identified biallelic variants in the EXOSC4 gene associated with neurological disorders:

• A homozygous variant in EXOSC4 (NM_019037.3:c.560T>C (p.[Leu187Pro])) has been linked to neurodevelopmental delay, brain calcifications, and failure to thrive in affected individuals .

• This EXOSC4 (p.Leu187Pro) variant is absent from publicly available variant databases (1000 Genomes, Exome Variant Server, and gnomAD) .

• Multiple in silico prediction tools (BayesDel, MetaRNN, REVEL GERP, LRT, MutationAssessor, MutationTaster, SIFT, and PROVEAN) predict this variant to be damaging/pathogenic .

• The affected site (NM_019037.3:c.560T) is highly conserved among 100 vertebrate genomes .

• Molecular analysis of this variant demonstrates:

  • Significant accumulation of RNAs normally processed or degraded by the RNA exosome

  • Reduction in polysome levels

  • Decreased steady-state levels of the mammalian EXOSC4-L187P protein

  • Decreased copurification with other RNA exosome subunits, suggesting reduced interaction with the complex

This adds EXOSC4 to the growing list of RNA exosome subunits linked to neurological deficits in humans.

How can gene knockdown approaches be optimized for studying EXOSC4 function?

Based on published research methodologies, optimize EXOSC4 knockdown studies as follows:

• Vector selection: Lentiviral shRNA vectors have been successfully used for EXOSC4 knockdown with infection efficiency >90% in cancer cell lines .

• Verification methods:

  • Confirm knockdown by both RT-PCR (mRNA level) and western blot (protein level)

  • Use fluorescence microscopy to visualize GFP expression from the vector

• Controls: Include appropriate non-targeting shRNA controls to account for non-specific effects.

• Functional assays: Multiple assays should be employed to comprehensively assess functional consequences:

  • Proliferation: CCK8 assays and colony formation assays

  • Cell cycle: Flow cytometry for cell cycle distribution

  • Migration and invasion: Transwell assays

  • Molecular pathway analysis: qPCR and western blot for downstream targets

• Timing considerations: Allow sufficient time (typically 48-72 hours post-infection) before conducting functional assays to ensure adequate knockdown.

When interpreting results, consider that EXOSC4 knockdown may have pleotropic effects due to its involvement in multiple RNA processing pathways.

What are potential reasons for discrepancies in EXOSC4 antibody detection between western blot and immunohistochemistry?

Discrepancies between western blot and IHC results for EXOSC4 detection may occur for several reasons:

• Protein conformation differences: Western blot detects denatured proteins while IHC detects proteins in their native conformation. EXOSC4 epitopes may be differentially exposed in these states.

• Fixation effects: Formalin fixation in IHC can mask epitopes recognized by certain antibodies .

• Subcellular localization: EXOSC4 localizes to both nucleus and cytoplasm, with possible variations in different tissue/cell types or under different conditions .

• Antibody specificity: Some antibodies may recognize specific post-translational modifications or isoforms that are differentially present in various contexts.

• Complex formation: In native tissues (IHC), EXOSC4 exists within the RNA exosome complex, potentially affecting epitope accessibility compared to denatured samples (WB).

• Antigen retrieval methods: Different methods (citrate buffer pH 6.0 vs. TE buffer pH 9.0) may yield different results in IHC .

To resolve discrepancies:

• Use multiple antibodies targeting different epitopes of EXOSC4

• Optimize antigen retrieval methods for IHC

• Include appropriate positive controls (e.g., HeLa cells for WB; human thyroid cancer tissue for IHC)

• Consider validating with additional methods (IF, IP) to confirm results

How should researchers interpret changes in EXOSC4 expression in the context of the entire RNA exosome complex?

When studying EXOSC4 expression changes, consider the following to properly interpret results in the context of the entire RNA exosome complex:

Research suggests that steady-state levels of mutant EXOSC4 protein may be decreased, and its ability to interact with other exosome components compromised, as seen with the L187P variant . These findings indicate that analysis of the entire complex is necessary for comprehensive understanding of EXOSC4 alterations.

What are promising approaches for developing more specific EXOSC4 targeting strategies?

Based on current research, several approaches show promise for more specific EXOSC4 targeting:

• Structure-guided antibody design: Using the known structure of the RNA exosome complex to design antibodies targeting unique, accessible epitopes on EXOSC4 that don't interfere with essential cellular functions.

• Conditional knockout models: Developing tissue-specific or inducible EXOSC4 knockout systems to better understand its role in different contexts without the complications of embryonic lethality often associated with core RNA processing factors.

• Domain-specific inhibitors: Creating small molecules or peptides that target specific functional domains of EXOSC4, particularly those involved in protein-protein interactions within the exosome complex.

• RNA-based therapies: Antisense oligonucleotides or siRNAs with delivery systems optimized for specific tissues (such as tumors overexpressing EXOSC4).

• Post-translational modification targeting: Identifying and targeting specific post-translational modifications unique to EXOSC4 in disease states.

These approaches require further validation but offer potential avenues for both research tools and therapeutic development, particularly in contexts where EXOSC4 is implicated in disease progression, such as epithelial ovarian cancer .

How might comparative studies of different RNA exosome components advance our understanding of EXOSC4?

Comparative studies of RNA exosome components can significantly enhance our understanding of EXOSC4 in several ways:

• Functional redundancy mapping: Systematic comparison of phenotypes resulting from depletion of different exosome components can reveal which functions are unique to EXOSC4 versus shared among multiple subunits.

• Evolutionary conservation analysis: Comparing the function of EXOSC4 orthologs across species (from yeast to humans) can identify core conserved functions versus species-specific adaptations.

• Disease association patterns: Analysis of the growing list of RNA exosome subunits linked to human diseases (including EXOSC4's association with neurological deficits ) may reveal patterns in how different components contribute to pathology.

• Structural interaction networks: Comprehensive protein-protein interaction studies can map how EXOSC4 fits into various configurations of the exosome complex under different cellular conditions.

• Tissue-specific expression patterns: Comparing expression profiles of all exosome components across tissues may explain why mutations in specific subunits affect certain tissues more severely than others.

Current evidence suggests that biallelic variants in different exosome components can lead to distinct but overlapping clinical presentations, particularly affecting the nervous system . Understanding why EXOSC4 variants specifically affect brain development and function requires this comparative approach.